Figure 5.

EL4.gp33 cells killed in vivo after immunization with dendritic cells (DCs) pulsed with gp33 protects against EL4 tumor development. (A) C57BL/6 mice were inoculated with mature gp33-DCs. On day 6, the control group was inoculated with PBS (control) and the rest of groups were inoculated with 2.5×10⁵ gp33-EL4 cells in the right flank (EL4.gp33^TcDC). On day 20, all groups were inoculated with 2×10⁵ EL4 cells in the left flank. In one group of mice CD8 cells were depleted employing an anti-CD8β monoclonal antibody (days 19, 23, 27 and 31) (EL4.gp3^TcDC anti-CD8). Tumor development was monitored over 50 days as described in theMethods section. The data correspond to 12 mice from three independent experiments, where ***p<0.001. Two-way analysis of variance (ANOVA) with Bonferroni post-test and log-rank test (Mantel-Cox). (B) C57BL/6 wt and BATF3^KO mice were inoculated with 3×10⁶ mature DCs (LPS 1 µg/mL 20 hours) incubated with gp33 peptide via intraperitoneal. On day 6, one group was inoculated with PBS (Tc wt DCs^gp33, Tc BATF3^KO DCs^gp33) and the other group was inoculated with 5×10⁵ gp33-EL4 cells in the right flank (TC wt EL4.gp33^TcDC, Tc BATF3^KO EL4.gp33^TcDC). Seven days later, mice were sacrificed, CD8⁺ Tc cells from the spleen and lymph nodes were enriched by MACS and transferred (6×10⁶ cells) into C57BL/6 wt mice, who had been inoculated with 1.5×10⁵ EL4 cell. Tumor development was monitored over 20 days as described in the Methods section. The data correspond to five mice from one experiment, where **p<0.01; ***p<0.001. Two-way ANOVA with Bonferroni post-test and log-rank test (Mantel-Cox).